Dr. Christos Liolios has a pharmacy degree from the Dep. of Pharmacy, National Kapodistrian University of Athens (NKUA), (2004), where he also did his master thesis in Pharmacy in pharmacognosy and chemistry of bioactive natural products (2005). In 2008, he received a scholarship from NCSR “Demokritos”, Athens for his PhD thesis on radiolabeled bombesin derivatives for SPECT (^99mTc/¹⁸⁸Re) & PET (⁶⁴Cu) tomography for diagnosis and therapy of prostate cancer (PCa), which he successfully defended in 2013 in the Pharmacy Dep. Univ. of Patras. In 2014 he joined, as a post-doctoral researcher, the Div. of Radiopharmaceutical Chemistry in the German Cancer Research Centre (DKFZ), Heidelberg, Germany, which has played a protagonistic role on the development of PET-diagnosis and endoradiotherapy of PCa during the last 6 years. In 2019 he returned to Greece and he is currently working as a Post-doctoral researcher in ΕΣΠΑ/ΕΔΒΜ34 for the “Development of ⁶⁸Ga-labeled magnetic iron nanoparticles targeting GRP (gastrin releasing peptide) and PSMA (prostate specific membrane antigen) receptors for molecular multimodality imaging with PET/MRI of PCa” with Dr. Penelope Bouziotis, and he is also affiliated in the Dep. Pharmacy NKUA in the lad of Med. Chemistry of Prof. A.Kolocouris.

Dr. Liolios has a strong background in radiochemistry, pharmacology/pharmacokinetics (in vitro/ in vivo assays) and medicinal chemistry (solid phase peptide synthesis, organic and bioconjugation chemistry). He has extensively worked on diagnostic/therapeutic molecules for PCa, in addition to molecules targeting receptors expressed on other types of cancer. His main scientific interest currently focuses on the development of theranostic molecules: 1) multi-targeting ligands for prostate specific membrane antigen/ gastrin releasing peptide receptors, which can be labeled either with diagnostic ⁶⁸Ga or therapeutic radionuclides ¹⁷⁷Lu, or 2) ligands combining targeted release of a toxophore in tumor cells and PET diagnosis of cancer foci.